Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

November 01, 1997; 49 (5) Articles

Delayed posthypoxic demyelination

Association with arylsulfatase A deficiency and lactic acidosis on proton MR spectroscopy

Jay A. Gottfried, Stephan A. Mayer, Dikoma C. Shungu, Yuan Chang, Jozef H. Duyn
First published November 1, 1997, DOI: https://doi.org/10.1212/WNL.49.5.1400
Jay A. Gottfried
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephan A. Mayer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dikoma C. Shungu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuan Chang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jozef H. Duyn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Delayed posthypoxic demyelination
Association with arylsulfatase A deficiency and lactic acidosis on proton MR spectroscopy
Jay A. Gottfried, Stephan A. Mayer, Dikoma C. Shungu, Yuan Chang, Jozef H. Duyn
Neurology Nov 1997, 49 (5) 1400-1404; DOI: 10.1212/WNL.49.5.1400

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
130

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Delayed demyelination is a rare and poorly understood complication of hypoxic brain injury. A previous case report has suggested an association with mild-to-moderate deficiency of arylsulfatase A. We describe a 36-year-old man who recovered completely from an episode of hypoxia related to drug overdose, and 2 weeks later progressed from a confusional state to deep coma. MRI showed diffuse white matter signal changes, and brain biopsy demonstrated a noninflammatory demyelinating process. Proton magnetic resonance spectroscopy revealed elevated choline and lactate and reduced N-acetyl aspartate signal in the affected white matter, consistent with demyelination and a shift to anaerobic metabolism. Arylsulfatase A activity from peripheral leukocytes was approximately 50% of normal, consistent with a "pseudodeficiency" phenotype. These findings confirm the hypothesis that relative arylsulfatase A deficiency predisposes susceptible individuals to delayed posthypoxic leukoencephalopathy and implicates lactic acidosis in the pathogenesis of this disorder.

Delayed posthypoxic demyelination is a rare and poorly understood complication of hypoxic brain injury. In the original descriptions, comatose patients found after a hypoxic insult would regain consciousness within 1 to 2 days, only to relapse irreversibly into coma days to weeks later.1,2 Concurrent histologic studies identified areas of pathology restricted to central white matter, with demyelination and relative axonal sparing.1,2 Despite the scarcity of this complication, a retrospective analysis of 2,360 victims of carbon monoxide (CO) poisoning indicates that as many as 2.75% of patients suffer from delayed neurologic sequelae.3 Although initially associated with CO intoxication, the syndrome may occur with hypoxia of any cause, including asphyxiation, cardiac arrest, and drug overdose. Its pathogenesis remains obscure.

The phenomenon of delayed posthypoxic demyelination spurs two intriguing questions. First, why is cerebral myelin damaged in the relative absence of other neuropathology? Hypoxia is a well-established mechanism of neuronal degeneration but less commonly targets myelin.4 Second, what accounts for the delay in the leukoencephalopathy? A recent case report has proposed that "pseudodeficiency" of arylsulfatase A, with consequent dysfunction of myelin metabolism, could be a critical factor in predisposing some individuals to delayed demyelination after hypoxia.5 In this report we describe a patient with delayed posthypoxic demyelination following a drug overdose, in whom proton magnetic resonance (MR) spectroscopy and lysosomal enzyme analysis were used to elucidate the pathogenesis of this disorder.

Case report. The patient is a 36-year-old man with a 20-year history of polysubstance abuse who was found by a family member lying face down in his bedroom, unconscious and cyanotic with shallow breathing. He was taken to a local hospital, where he was intubated for airway protection. Urine toxicology screen was positive for benzodiazepines, opiates, and amphetamines; respiratory arrest was attributed to an overdose of morphine sulfate. The patient awakened from coma after 48 hours, and thereafter his condition improved rapidly. He was discharged on hospital day eight after making a complete neurologic recovery.

On day 24 after the overdose, the patient began to behave strangely. His speech was idiosyncratic and bizarre. He became withdrawn, forgetful, and confused, attempting to open a car door with a quarter. The following day his behavior worsened. He developed persistent myoclonic jerks in his right thigh. He was unable to feed or dress himself, required the careful attendance of family members, and became incontinent. The patient refused to go to sleep without clutching the same quarter in his hand.

When he was readmitted on day 26 after the overdose, a repeat toxicology screen was negative, and serum electrolytes and blood counts were normal. The CSF contained 2 WBC and 249 RBC per mm3 with normal protein and glucose. CSF cultures were negative. MRI revealed extensive bilateral hyperintensities on T2-weighted images throughout hemispheric white matter. Over the next 3 days the patient became stuporous and developed spastic quadraparesis.

On day 34 after the overdose he was intubated and transferred to the Columbia-Presbyterian Neuro-ICU for further care. On admission, temperature was 101.4 °F, heart rate 140, blood pressure 132/70 mm Hg, and respirations 30 and labored. He was deeply comatose and profoundly diaphoretic, with severe spastic quadraparesis, spontaneous knee and ankle clonus, and flexion-withdrawal responses to noxious stimuli. Pupillary, oculocephalic, corneal, and gag reflexes were intact. Snout, palmomental, and glabellar reflexes were prominent. His hospital course was complicated by dysautonomia with central hyperventilation, paroxysmal tachycardia, and high fevers. MRI revealed widespread increased T2 signal changes throughout the deep hemispheric white matter, and bilateral 0.5-cm diameter foci of increased T2 and decreased T1 signal in globus pallidus(figure 1). Biopsy of the right anterior temporal lobe was performed on day 36 after the overdose to exclude acute disseminated encephalomyelitis. The specimen showed normal cortex, but widespread patchy demyelination with axonal sparing in the underlying white matter(figure 2). Immunohistochemical staining demonstrated numerous reactive astrocytes and macrophages scattered throughout the white matter, with no evidence of acute or chronic inflammation. Until the results of the biopsy were available, the patient was treated with high-dose methylprednisolone, without clinical effect. HIV-1 titers, heavy-metal screen, and CSF oligoclonal bands were negative.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 1. Coronal (A) and axial (B) T2-weighted MRI showing severe widespread demyelination of the corona radiata and centrum semiovale. Two discrete foci of increased T2 signal involving the globus pallidus are also evident in panel A.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 2. (A) Open brain biopsy sample demonstrates normal cortex (left); however, subcortical white matter(right) is hypercellular with patchy loss of myelin (Luxol Fast Blue/PAS, 4× magnification). (B) Hypercellular white matter with numerous gemistocytic astrocytes and macrophages. Although stain shows paucity of myelin, Bielschowsky stain (not shown) indicates relative preservation of axons (Luxol Fast Blue/PAS, 20× magnification). (C) Scattered gliofibrillar acidic protein (GFAP) positive, stellate shaped reactive astrocytes in white matter (GFAP immunostain, 20× magnification). (D) Numerous cells with cytoplasmic reactivity for MAC-1 (a macrophage marker) are found throughout white matter as a response to myelin loss/degradation(MAC-1 immunostain, 20× magnification). (All magnifications are before 14% reduction.)

Multisection 1H magnetic resonance spectroscopic imaging (MRSI) was performed on day 65 after the overdose using a 1.5-T GE Signa scanner with a standard quadrature head coil (GE Medical Systems, Milwaukee, WI), according to the method of Duyn et al.6 A section-interleaved spin echo sequence with octagonally tailored outer volume presaturation pulses was used to suppress fat signals from the scalp, skull, and calvarial marrow. Water suppression was achieved with a single chemical shift selective (CHESS) pulse followed by spoiler gradients. Four 15-mm brain sections, with 3.5-mm intersection gaps, were selected along the anterior commissure-posterior commissure line. MRSI data were recorded using a TE of 280 ms, a TR of 2,300 ms, a field of view of 240 mm, 32 × 32 phase-encoding steps with circular k-space sampling, and 256 points along the signal acquisition domain. The data were zero-filled once along the acquisition domain and then processed by standard fast Fourier transform algorithm. The nominal size of each of the resulting array of 32 × 32 volume elements was 0.84 ml (0.75 × 0.75 × 1.5 cm). Routine MR images were obtained to provide an accurate anatomic correlation of the MRSI images. Compared with the spectrum of a healthy age-matched volunteer,1 H-MR spectroscopy of the deep hemispheric white matter of our patient showed reduced N-acetyl-aspartate (NAA), markedly elevated choline, and elevated lactate (figure 3). By contrast, these spectra were relatively normal throughout the gray matter of the cerebral cortex.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 3. Representative 1H MRSI spectra selected from volume elements in the periventricular white matter (a) and the occipital gray matter (c). For comparison, spectra obtained from corresponding locations in the brain of a normal volunteer are shown in panels (b) and (d). Note the lactate (lac) methyl peak at 1.33 ppm and the dramatic decrease of N-acetyl-aspartate (naa) (2.02 ppm) and increase of choline (cho) (2.23 ppm) in the white matter of the patient compared with control. Although relative metabolite levels are also abnormal in the gray matter spectra of the patient compared with control, they are better preserved than in the white matter, and the lactate methyl peak is absent.

Blood was collected and the patient's cultured leukocytes were analyzed for leukodystrophies (Mayo Medical Laboratories, Rochester, MN). Arylsulfatase A activity was measured using an artificial substrate and determined to be 2.1 units/1010 cells, which is approximately 50% of normal activity (normal range >2.5 units/1010 cells). By contrast, enzymatic activities of hexosaminidase A, β-galactosidase, and galactosyl-ceramideβ-galactosidase were normal, as were plasma levels of very long chain fatty acids and phytanic acid.

Three months after the overdose, the patient regained the ability to follow commands consistently. Six months after the overdose, he was alert and conversant but intermittently disoriented, with severe anterograde and retrograde amnesia. He had persistent spasticity with limited dexterity of the arms and legs but was able to walk with assistance. Percutaneous gastrostomy and tracheotomy tubes had been removed, although he remained unable to feed himself.

Discussion. Our patient's relapsing clinical course and radiologic findings are consistent with delayed posthypoxic demyelination.1,2 In particular, the MRI signal abnormalities in deep hemispheric white matter and globus pallidus (seeFigure 1) closely overlap the distinctive histopathology described in previous case reports of this disorder.2 Brain biopsy confirmed the presence of noninflammatory demyelination of the deep white matter without neuronal or axonal involvement (seefigure 2).

Although the pathologic hallmarks of delayed posthypoxic demyelination are well described, the pathophysiology of this disorder is poorly understood. Investigators initially believed that CO was directly myelinotoxic, but observation of the syndrome after a variety of hypoxic insults led to the consideration of other possibilities, including cerebral edema, vascular injury, and delayed-type hypersensitivity reactions.1,2 Although researchers have successfully reproduced selective white matter injury in a number of animal models,7-9 the underlying mechanism remains elusive.

Weinberger et al.5 have proposed that an impairment of myelin metabolism might play a role in the pathogenesis of delayed posthypoxic demyelination. In their case report, a 34-year-old man who developed this disorder after a drug overdose was shown to have a reduction of arylsulfatase A activity to 10 to 30% of normal values. Arylsulfatase A is a lysosomal enzyme that is responsible for the hydrolysis of cerebroside sulfate and other sulfolipids (sulfatides) that comprise up up to 4% of myelin lipid in both the central and peripheral nervous systems. The sulfatides are anionic glycolipids that may be essential to membrane integrity and may participate as cofactors for the Na+/K+-ATPase and the GABA, serotonin, and opiate receptors.10

Complete absence of arylsulfatase A causes a lysosomal accumulation of sulfatide within oligodendrocytes and Schwann cells and disrupts myelin metabolism, resulting clinically in metachromatic leukodystrophy (MLD), a congenitally acquired disease that is inherited as an autosomal recessive trait.10 A relative reduction of arylsulfatase A activity may occur in MLD heterozygotes but is more often found in healthy individuals in a condition called arysulfatase A "pseudodeficiency," which is caused by allelic mutations of the gene that gives rise to MLD. This allele occurs commonly in the general population, with a frequency of up to 15%,10 and contains a pair of mutations (A to G transitions), one that causes loss of an N-glycosylation site, the other that disrupts a polyadenylation signal.11 The enzymatic product of this mutated gene is catalytically intact, but is 3 to 4 kD smaller, underglycosylated, and more unstable than the normal protein. Despite these structural differences, the residual arylsulfatase A activity(between 10 to 50% of normal) is generally sufficient to prevent the accumulation of sulfatide, and carriers of this allele are asymptomatic.10

The identification of arylsulfatase A "pseudodeficiency" in a patient with delayed posthypoxic demyelination prompted Weinberger et al.5 to speculate that this normally asymptomatic condition might predispose a small percentage of patients exposed to hypoxia to delayed white matter loss. The authors proposed that the suboptimal arylsulfatase A activity in these individuals would be unable to sustain an accelerated period of remyelination following the initial hypoxic injury; moreover, the persistent failure of myelin metabolism would gradually permit the accumulation of lysosomal sulfatides to toxic proportions, a hypothesis that would elegantly account for the paradoxical delay of demyelination.5

In this case report, we provide evidence for a second patient with delayed posthypoxic demyelination who was found to have a reduction of arylsulfatase A activity to approximately 50% of normal. This finding supports the idea that relative arylsulfatase A deficiency might predispose individuals to delayed leukopathy after hypoxic injury. We emphasize that while"pseudodeficiency" has not been directly linked to clinical symptoms, there is some evidence implicating relative arylsulfatase A deficiency in certain forms of neuropathology, including neuropsychiatric illness,12 movement disorders,13 multiple sclerosis,14 and neurologic complications of alcoholism.15

The 1H-MR spectrum derived from our patient (seefigure 3) is consistent with a robust demyelinating process but differs from other white matter diseases in that a prominent lactate signal was identified. NAA, a neuron-specific marker,16 was reduced in deep white matter and is indicative of neuronal loss, or conversely, of a gain of non-neuronal(NAA-negative) cells. This latter possibility seems likely, given the degree of reactive astrocytosis observed pathologically (seefigure 2). Choline is a measure of membrane turnover and lipid metabolism,16 and its elevation in our patient is consistent with demyelination, which was corroborated by pathologic examination. Proton MR studies of multiple sclerosis and lupus erythematosus involving the CNS have failed to identify elevated lactate in involved white matter.17,18

The spectral peak of lactate in our patient suggests a conversion of aerobic metabolism to anaerobic energy production and complements previous findings in cats, whereby the application of subtotal brain ischemia elicited a preferential increase of lactate in central white matter.9 Either decreased energy substrate (e.g., hypoxia) or increased energy demands (e.g., neuronal stimulation or remyelination) may favor glycolysis and lactate production19; our patient's clinical course satisfies both of these conditions. Alternate explanations for the increase in lactate include reductions of cerebral blood flow or lactate sequestration within cellular elements that diminish its efflux from the brain.19 The abundance of macrophages detected in deep white matter is consistent with this latter idea.

Is lactate more a cause or a consequence of the white matter deterioration? Using rats exposed to mitochondrial neurotoxins, Jenkins et al.20 showed that the spectroscopic detection of lactate preceded evidence of neuronal lesions on T2-weighted MRI, implicating a causal role for lactate in the onset of neurodegenerative disease. It is intriguing to speculate that in the setting of relative enzyme deficiency, failure of oxidative metabolism might sufficiently disable arylsulfatase A activity to compromise myelin metabolism. The shift to glycolytic energy production and consequent reduction of ATP might interrupt a variety of cellular events essential to normal sulfatide turnover, such as lysosomal acidification, which may be critical to arylsulfatase A dimerization and function.10 On the other hand, the presence of lactate per se might interfere with myelin turnover. For example, a number of anions behave as inhibitors of arylsulfatase A, including sulfate, phosphate, and fluoride10; it is possible that lactate anion might reduce sulfatide hydrolysis to a clinically significant level. Alternatively, the presence of lactic acid in the millimolar range might reduce local intracellular pH and impair arylsulfatase A activity. In this regard, it is notable that the activity of arylsulfatase A (in multiple sulfatase deficiency) is dramatically reduced at low pH.10

Further studies are necessary to elucidate the biochemical basis for delayed posthypoxic demyelination. With the presentation of a second case report of arylsulfatase A deficiency in a patient with this disorder, we hope that our findings will stimulate research in this area.

Footnotes

  • Received February 25, 1997. Accepted in final form May 29, 1997.

References

  1. 1.↵
    Plum F, Posner JB, Hain RF. Delayed neurological deterioration after anoxia. Arch Intern Med 1962;110:18-25.
    OpenUrlCrossRef
  2. 2.↵
    Ginsberg MD. Delayed neurological deterioration following hypoxia. Adv Neurol 1979;26:21-47.
    OpenUrl
  3. 3.↵
    Choi IS. Delayed neurologic sequelae in carbon monoxide intoxication. Arch Neurol 1983;40:433-435.
    OpenUrl
  4. 4.↵
    Brierley JB, Graham DI. Hypoxia and vascular disorders of the central nervous system. In: Adams JH, Corsellis JAN, Duchen LW, eds. Greenfield's Neuropathology. London: Arnold, 1984:125-156.
  5. 5.↵
    Weinberger LM, Schmidley JW, Schafer IA, Raghavan S. Delayed postanoxic demyelination and arylsulfatase-A pseudo-deficiency. Neurology 1994;44:152-154.
    OpenUrlPubMed
  6. 6.↵
    Duyn JH, Gillen J, Sobering G, van Zijl PC, Moonen CTW. Multisection proton MR spectroscopic imaging of the brain. Radiology 1993;188:277-282.
    OpenUrl
  7. 7.↵
    Ginsberg MD, Myers RE. Experimental carbon monoxide encephalopathy in the primate. I. Physiologic and metabolic aspects. Arch Neurol 1974;30:202-208.
    OpenUrlCrossRef
  8. 8.
    Ginsberg MD, Myers RE, McDonagh BF. Experimental carbon monoxide encephalopathy in the primate. II. Clinical aspects, neuropathology, and physiologic correlation. Arch Neurol 1974;30:209-216.
    OpenUrlCrossRef
  9. 9.↵
    Welsh FA, O'Connor MJ, Marcy VR. Effect of oligemia on regional metabolite levels in cat brain. J Neurochem 1978;31:311-319.
    OpenUrl
  10. 10.↵
    Kolodny EH. Metachromatic leukodystrophy and multiple sulfatase deficiency: sulfatide lipidosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic basis of inherited disease. 6th ed. Vol 2. New York: McGraw-Hill, 1989:1721-1750.
  11. 11.↵
    Gieselmann V, Polten A, Kreysing J, von Figura K. Arylsulfatase A pseudodeficiency: loss of a polyadenylation signal and N-glycosylation site. Proc Natl Acad Sci USA 1989;86:9436-9440.
    OpenUrl
  12. 12.↵
    Hohenschutz C, Friedl W, Schlor KH, et al. Probable metachromatic leukodystrophy/pseudodeficiency compound heterozygote at the arylsulfatase A locus with neurological and psychiatric symptomology. Am J Med Genet 1988;31:169-175.
    OpenUrlPubMed
  13. 13.↵
    Sangiorgi S, Mochi M, Capellari S, Pietrobello MV, Marchello L, Montagna P. Movement disorders in arylsulfatase A pseudodeficiency (ASAPD). Neurology 1992;42(suppl 3):155.
  14. 14.↵
    Kappler J, Potter W, Gieselmann V, Kiessling W, Friedl W, Propping P. Phenotypic consequences of low arylsulfatase A genotypes(ASAp/ASAp and ASA-/ASAp): Does there exist an association with multiple sclerosis? Dev Neurosci 1991;13:228-231.
    OpenUrl
  15. 15.↵
    Park DS, Poretz RD, Stein S, Nora R, Manowitz P. Association of alcoholism with the N-glycosylation polymorphism of pseudodeficient human arylsulfatase A. Alcohol Clin Exp Res 1996;20:228-233.
    OpenUrl
  16. 16.↵
    Vion-Dury J, Meyerhoff DJ, Cozzone PJ, Weiner MW. What might be the impact on neurology of the analysis of brain metabolism by in vivo magnetic resonance spectroscopy? J Neurol 1994;241:354-371.
    OpenUrl
  17. 17.↵
    Roser W, Hagberg G, Mader I, et al. Proton MRS of gadolinium-enhancing MS plaques and metabolic changes in normal-appearing white matter. Magn Reson Med 1995;33:811-817.
    OpenUrlPubMed
  18. 18.
    Davie CA, Feinstein A, Kartsounis LD, et al. Proton magnetic resonance spectroscopy of systemic lupus erythematosus involving the central nervous system. J Neurol 1995;242:522-528.
    OpenUrl
  19. 19.↵
    Prichard J. What the clinician can learn from MRS lactate measurement. NMR Biomed 1991;4:99-102.
    OpenUrlPubMed
  20. 20.↵
    Jenkins BG, Brouillet E, Chen YCI, et al. Non-invasive neurochemical analysis of focal excitotoxic lesions is models of neurodegenerative illness using spectroscopic imaging. J Cereb Blood Flow Metab 1996;16:450-461.
    OpenUrl

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 99 (6)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise